The Patent Finder
MO

ModernaTX, Inc.

First filing 2011
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Moderna Therapeutics, Inc. (to 2016)

272 patents currently held

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.

The next term ends in Aug 2031. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2031
Next term end
133
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Modified Polynucleotides US 10,501,512
Cited by 178 later US patents, top 1% of utility patents granted in 2019 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Ends Mar 2033 · High confidence
Also notable
Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides US 10,501,513
Cited by 117 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Ends Mar 2033 · High confidence
Also notable
Modified Polynucleotides Encoding Hepatitis a Virus Cellular Receptor 2 US 9,675,668
Cited by 173 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Ends May 2034 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 30, 2026
    The maintenance fee for Mrna Combination Therapy for the Treatment of Cancer (US 11,660,341) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
  • 6 fees due Dec 9 to 27, 2026 · next Dec 9
  • 5 fees due Jan 2 to 28, 2027 · next Jan 2
  • 9 fees due Feb 4 to 27, 2027 · next Feb 4
  • 6 fees due Mar 5 to 26, 2027 · next Mar 5
  • 8 fees due Apr 1 to 30, 2027 · next Apr 1
  • 6 fees due May 5 to 26, 2027 · next May 5
  • 12 fees due Jun 3 to 30, 2027 · next Jun 3
  • 9 fees due Jul 2 to 28, 2027 · next Jul 2
  • 8 fees due Aug 9 to 27, 2027 · next Aug 9
  • 8 fees due Sep 1 to 29, 2027 · next Sep 1
  • 2 fees due Oct 5 to 30, 2027 · next Oct 5
  • 3 fees due Nov 10 to 14, 2027 · next Nov 10

Which patents, and when each one lapses · Pro

Recent changes

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,822,663Engineered Nucleic Acids and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,181,319Engineered Nucleic Acids and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,447,164Engineered Nucleic Acids and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,937,233Engineered Nucleic Acids and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,657,295Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,701,965Engineered Nucleic Acids and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 10,064,959Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,334,328Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 8,710,200Engineered Nucleic Acids Encoding a Modified Erythropoietin and Their Expression
In force
 · High confidence
In forceHigh confidence
US 9,186,372Split Dose Administration
In force
 · High confidence
In forceHigh confidence
10 of 272 patents shown.
Pro members see all 272.
Pro members: see all 272 patents
Also on record, not counted in the 272: 1 patent in force now held by others · 16 patents ended · 165 applications pending · 215 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited